secwatch.observer — SEC 8-K summary
======================================

Issuer:     Processa Pharmaceuticals, Inc. (PCSA)
CIK:        0001533743
Form:       8-K
Filed at:   2025-06-17T23:59:59+00:00
Accession:  0001641172-25-015355
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Processa grants Intact exclusive option to license PCS12852 for up to $452.5M milestones plus royalties
--------------------------------------------------------------------------------

- Near-term payments: $2.5M option exercise fee plus 3.5% equity stake in Intact upon closing.
- Up to $20M in development/regulatory milestones and over $432.5M in commercial milestones on net sales.
- Double-digit royalty on worldwide net sales (ex-South Korea); Processa must share 60% of cash payments with licensor Yuhan.
- PCS12852 is a Phase 2-ready 5-HT4 agonist for diabetic gastroparesis with positive Phase 2a safety/efficacy data.
- Definitive license agreement subject to 120-day diligence, extension for $30K, and Yuhan amendment.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1533743/000164117225015355/0001641172-25-015355-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1533743/000164117225015355/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-015355

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer